Papillary Fibroelastoma, Unusual Cause of Stroke in a Young Man
J Cardiothorac Surg 12:33, Grolla, E.,et al, 2017
Embolic Strokes of Unknown Source and Cryptogenic Stroke: Implications in Clinical Practice
Front Neurol 7:1-16, Nouh, A.,et al, 2016
Which Oral Anticoagulation for Atrial Fibrillation?
JAMA 315:2117-2118, The Medical Letter, 2016
Cost-Effectiveness of Oral Anticoagulants for Ischemic Stroke Prophylaxis Among Nonvalvular Atrial Fibrillation Patients
Stroke 47:1555-1561, Shah, A.,et al, 2016
Closure Versus Medical Therapy for Preventing Recurrent Stroke in Patients with Patent Foramen Ovale and a History of Cryptogenic Stroke or Transient Ischemic Attack
Stroke 47:e188-e189, Li, J.,et al, 2016
Managing Risk After Intracerebral Hemorrhage in Concomitant Atrial Fibrillation and Cerebral Amyloid Angiopathy
Stroke 47:e190-e192, Stoker, T.B.,et al, 2016
Clinicopathologic Conference, Somnolence due to the Cerebral Fat Embolism Syndrome
NEJM 375:370-378, Case 23-2016, 2016
The Value of Transesophageal Echocardiography for Embolic Strokes of Undetermined Source
Neuol 87:988-995, Katsanos, A.H.,et al, 2016
Left Atrial Appendage Function and Stroke Risk
Stroke 46:3554-3559, Yaghi, S.,et al, 2015
Acute Ischemic Stroke in Pediatric Patients
Stroke 46:e32-e33, Mittal, S.O.,et al, 2015
Rates of Ischemic Stroke During Warfarin Treatment for Atrial Fibrillation
Stroke 46:1120-1122, Tung, J.M.,et al, 2015
Stroke Prevention in Atrial Fibrillation
JAMA 313:1950-1962, Lip, G.Y.H. & Lane, D.A., 2015
Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation: Current Status, Special Situations, and Unmet Needs
Lancet 386:303-310, Verheugt, F.W.A. & Granger, C.B., 2015
Selective Vulnerability of Cortical Border Zone to Microembolic Infarct
Stroke 46:1864-1869, Bergui, M.,et al, 2015
Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation
NEJM 373:823-833, Douketis,J.D.,et al, 2015
Percutaneous Left Atrial Appendage Closure:Technical Aspects and Prevention of Periprocedural Complications with the Watchman Device
Workd J Cardiol 26:65-75, Mobius-Winkler,S.,et al, 2015
Association of Cerebral Microbleeds with Mortality in Stroke Patients Having Atrial Fibrillation
Neurol 83:1308-1315,1304, Song, T.J.,et al, 2014
Infections of the Nervous System, (Bacterial, Fungal, Spirochetal, Parasitic) and Sarcoidosis, Lyme Disease (Erythema Chronicum Migrans; Borreliosis
Adams & Victors Principles of Neurology, Chp 32, pg 728, Ropper, A.H.,et al, 2014
Recognition and Management of Withdrawal Delirium
NEJM 371:2109-2113, Schuckit, M.A., 2014
Cerebrovascular Events in 21 105 Patients with Atrial Fibrillation Randomized to Edoxaban Versus Warfarin
Stroke 45:2372-2378, Giugliano, R.P.,et al, 2014
Perioperative Atrial Fibrillation and the Long-Term Risk of Ischemic Stroke
JAMA 312:616-622, Gialdini, G.,et al, 2014
Preadmission Oral Anticoagulant Treatment and Clinical Outcome Among Patients Hospitalized with Acute Stroke and Atrial Fibrillation
Stroke 45:168-175, Johnsen, S.P.,et al, 2014
Comparison of the Efficacy and Safety of New Oral Anticoagulants with Warfarin in Patients with Atrial Fibrillation: A Meta-Analysis of Randomised Trials
Lancet 383:955-962,931, Ruff, C.T.,et al, 2014
Factor Xa Inhibitors vs Warfarin for Preventing Stroke and Thromboembolism in Patients with Atrial Fibrillation
JAMA 311:1150-1151, Bruins Slot, K.M.H. & Berge, E., 2014
Faxtor Xa Inhibitors Versus Vitamin K Antagonists for Preventing Cerebral or Systemic Embolism in Patients with Atrial Fibrillation
Stroke 44:e165-e167, Bruins, K.M.H., & Berge, E., 2013
Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke
NEJM 368:1092-1100,1152, Carroll, J.D.,et al, 2013
Percutaneous Closure of Patent Foramen Ovale in Cryptogenic Embolism
NEJM 368:1083-1091,1152, Meier, B.,et al, 2013
Summary of Evidence-Based Guideline: Periprocedural Management of Antithrombic Medications in Patients with Ischemic Cerebrovascular Disease
Neurol 80:2065-2069, Armstrong, M.,et al, 2013
An Index to Identify Stroke-Related vs Incidental Patent Foramen Ovale in Cryptogenic Stroke
Neurol 81:619-625,619, Kent, D.M.,et al, 2013
Patent Foramen Ovale and Cryptogenic Stroke
Stroke 44:2676-2678, Furlan, A.J. and Jauss, M., 2013
Management of Anticoagulation Before and After Elective Surgery
www.uptodate.com Dec. 2012, Lip, G. & Douketis, J., 2012
Closure or Medical Therapy for Cryptogenic Stroke with Patent Foramen Ovale
NEJM 366:991-999,1048, Furlan,A.J.,et al, 2012
Self-Monitoring of Oral Anticoagulation: Systematic Review and Meta-Analysis of Individual Patient Data
Lancet 379:322-34, Heneghan,C., 2012
Critique of Apixaban Versus Warfarin in Patients with Atrial Fibrillation
Stroke 43:922-923, Nedeltchev,K, 2012
Secondary Prevention after Ischemic Stroke or Transient Ischemic Attack
NEJM 366:1914-1922;, Davis, S.M. & Donnan, G.A., 2012
Spinal Haemorrhage During Anticoagulant Regimen for Thromboprophylaxis: A Unique Form of Central Nervous System Haemorrhage
JNNP 83:746-752, Furlan, J.C.,et al, 2012
Stroke and Bleeding in Atrial Fibrillation with Chronic Kidney Disease
NEJM 367:625-635, Olesen, J.B.,et al, 2012
Critique of Closure or Medical Therapy for Cryptogenic Stroke with Patent Foramen Ovale
Stroke 43:3147-3149, Thaler, D.E.,et al, 2012
Clinicopathologic Conference, Acute Ischemic Stroke due to Basilar Artery Embolism. Patent Foramen Ovale
NEJM 367:1450-1460, Case 31-2012, 2012
Left Atrial Catheter Ablation and Ischemic Stroke
Stroke 43:265-270, Haeusler, K.G.,et al, 2012
Using Dabigatran in Patients with Stroke A Practical Guide for Clinicians
Stroke 43:271-279, Alberts, M.J.,et al, 2012
Patent Foramen Ovale Closure and Medical Treatments for Secondary Stroke Prevention
Stroke 43:422-431, Kitsios,G.D.,et al, 2012
Apixaban versus Warfarin in Patients with Atrial Fibrillation
NEJM 365:981-992,1052, Granger, C.B.,et al, 2011
Dronedarone in High-Risk Permanent Atrial Fibrillation
NEJM 365:2268-2276,2321, Connoly, S.J.,et al, 2011
Catheter Ablation for Atrial Fibrillation
NEJM 365:2296-2304, Wazni, O.,et al, 2011
Apixaban in Atrial Fibrillation From Bleeding Cows to 21st Century Medicinal Chemistry
Stroke 42:2376-2378, Cucchiara, B.L.,et al, 2011
Rivaroxaban versus Warfarin in Nonvavular Atrial Fibrillation
NEJM 365:883-891, 952, Patel, M.R.,et al, 2011
Hereditary Hemorrhagic Telangiectasia (Osler-Weber-Rendu Syndrome)
UpToDate, Feb, Shovlin, C., 2011
Dabigatran Etexilate versus Warfarin in Management of Non-Valvular Atrial Fibrillation in UK Context: Quantitative Benefit-Harm and Economic Analyses
BMJ 343:d6333, Pink, J.,et al, 2011
A New Landscape for Stroke Prevention in Atrial Fibrillation
Stroke 42:3316-3322, Banerjee, A.,et al, 2011